Surveillance for Metastasis in High-Risk Uveal Melanoma Patients: Standard versus Enhanced Protocols

被引:2
作者
Yesiltas, Yagmur Seda [1 ]
Zabor, Emily C. [2 ]
Wrenn, Jacquelyn [1 ]
Oakey, Zackery [3 ]
Singh, Arun D. [1 ]
机构
[1] Cole Eye Inst, Dept Ophthalm Oncol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Lerner Res Inst, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA
[3] Hoag Mem Hosp, Blue Coast Retina, Irvine, CA 92618 USA
关键词
liver metastasis; surveillance; survival; uveal melanoma; LIVER METASTASES; HEPATIC ULTRASONOGRAPHY; COMPUTED-TOMOGRAPHY; MALIGNANT-MELANOMA; SURVIVAL; MANAGEMENT; RESECTION; TRIAL; MRI;
D O I
10.3390/cancers15205025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: to evaluate the effectiveness of enhanced surveillance protocols (EP) utilizing high frequency (HF) or enhanced modality (EM) compared to the standard protocol (SP) in detecting metastasis and determining their impact on overall survival (OS) in high-risk uveal melanoma (UM) patients. Methods: A total of 87 consecutive patients with Class 2 (high risk) primary UM were enrolled, with negative baseline systemic staging. The patients underwent systemic surveillance with either SP (hepatic ultrasonography [US] every 6 months) or EP (either HF [US every 3 months] or EM [incorporation hepatic computed tomography/magnetic resonance imaging]) following informed discussion. The main outcome measures were largest diameter of largest hepatic metastasis (LDLM), number of hepatic metastatic lesions, time to detection of metastasis (TDM), and OS. Results: This study revealed significant differences in LDLM between surveillance protocols, with the use of EP detecting smaller metastatic lesions (HF, EM, and SP were 1.5 cm, 1.6 cm, and 6.1 cm, respectively). Patients on the EM protocol had a lower 24-month cumulative incidence of >3 cm metastasis (3.5% EM vs. 39% SP; p = 0.021), while those on the HF protocol had a higher 24-month cumulative incidence of <= 3 cm metastasis compared to SP (31% HF vs. 10% SP; p = 0.017). Hazard of death following metastasis was significantly reduced in the EP (HR: 0.25; 95% CI: 0.07, 0.84), HF (HR: 0.23; 95% CI: 0.06, 0.84), and EM (HR: 0.11; 95% CI: 0.02, 0.5) groups compared to SP. However, TDM and OS did not significantly differ between protocols. Conclusions: Enhanced surveillance protocols improved early detection of hepatic metastasis in UM patients but did not translate into a survival advantage in our study cohort. However, early detection of metastasis in patients receiving liver-directed therapies may lead to improved overall survival.
引用
收藏
页数:12
相关论文
共 50 条
[31]   Surveillance Versus Adjuvant Radiotherapy for Patients With High-Risk Stage I Seminoma [J].
Mortensen, Mette S. ;
Bandak, Mikkel ;
Kier, Maria G. G. ;
Lauritsen, Jakob ;
Agerbk, Mads ;
Holm, Niels V. ;
von der Maase, Hans ;
Daugaard, Gedske .
CANCER, 2017, 123 (07) :1212-1218
[32]   Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients [J].
Kumar, Nikhil ;
Singh, Mithalesh Kumar ;
Singh, Lata ;
Lomi, Neiwete ;
Meel, Rachna ;
Pushker, Neelam ;
Sen, Seema ;
Kashyap, Seema .
HUMAN CELL, 2023, 36 (01) :342-352
[33]   Non-Conditional and Conditional Metastasis of Uveal Melanoma Per Millimeter-By-Millimeter in Thickness in 8034 Patients [J].
Sener, Hidayet ;
Bansal, Rolika ;
Catapano, Thomas ;
Shields, Jerry A. ;
Shields, Carol L. .
SEMINARS IN OPHTHALMOLOGY, 2024,
[34]   Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma [J].
Suwajanakorn, D. ;
Lane, A. M. ;
Go, A. K. ;
Hartley, C. D. ;
Oxenreiter, M. ;
Wu, F. ;
Gragoudas, E. S. ;
Sullivan, R. J. ;
Montazeri, K. ;
Kim, I. K. .
MELANOMA RESEARCH, 2024, 34 (04) :319-325
[35]   Improved Uveal Melanoma Copy Number Subtypes Including an Ultra-High-Risk Group [J].
Lalonde, Emilie ;
Ewens, Kathryn ;
Richards-Yutz, Jennifer ;
Ebrahimzedeh, Jessica ;
Terai, Mizue ;
Gonsalves, Cann F. ;
Sato, Takami ;
Shields, Carol L. ;
Ganguly, Arupa .
OPHTHALMOLOGY SCIENCE, 2022, 2 (02)
[36]   Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma [J].
Spagnolo, Francesco ;
Croce, Elena ;
Boutros, Andrea ;
Tanda, Enrica ;
Cecchi, Federica ;
Mascherini, Matteo ;
Solari, Nicola ;
Cafiero, Ferdinando ;
Queirolo, Paola .
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (05) :403-413
[37]   Rapid COJEC versus standard induction therapies for high-risk neuroblastoma [J].
Peinemann, Frank ;
Tushabe, Doreen A. ;
van Dalen, Elvira C. ;
Berthold, Frank .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (05)
[38]   Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma [J].
Ewens, K. G. ;
Lalonde, E. ;
Richards-Yutz, J. ;
Shields, C. L. ;
Ganguly, A. .
BMC CANCER, 2018, 18
[39]   Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma [J].
K. G. Ewens ;
E. Lalonde ;
J. Richards-Yutz ;
C. L. Shields ;
A. Ganguly .
BMC Cancer, 18
[40]   Canadian Melanoma Conference Recommendations on High-Risk Melanoma Surveillance: A Report from the 14th Annual Canadian Melanoma Conference; Banff, Alberta; 20-22 February 2020 [J].
Lee, Christina W. ;
McKinnon, J. Gregory ;
Davis, Noelle .
CURRENT ONCOLOGY, 2021, 28 (03) :2040-2051